Framework for personalized prediction of treatment response in relapsing remitting multiple sclerosis

Table 9 Comparison of therapy effectiveness for the relapse model

DMT*	Slope coefficient^a	Sample size when DMT* was taken	Sample size when DMT* was not taken	p-value
Dimethylfumarat	−0.6918	134	307	0.016
Fingolimod	0.0423	128	112	0.860
Natalizumab	−0.4376	234	2182	0.019

DMT* highest ranked disease modifying therapy.
^a Derived from a survey-weighted negative binomial generalized linear model where negative sign indicates lower disease activity

ISSN: 1471-2288